Safety and Efficacy of DIT309 in Advanced Bone and Soft Tissue Sarcomas

This is a open-Label, dose-escalation study to evaluate the safety, tolerability and antitumor activity of DIT309 in subjects with advanced bone and soft tissue sarcomas.The study also plan to explore the Maximum Tolerated Dose (MTD) and determine the Recommended Phase II Dose (RP2D) of the CAR-T cell therapy.

Trial Details

NCT ID
NCT07052383
Phase
PHASE1
Sponsor
Tcelltech Inc.
Status
RECRUITING
Cancer Type
Osteosarcoma Sarcoma
Interventions
  • DIT309 cell injection
Locations (sample)
  • Shanghai, Shanghai Municipality, China|31.22222,121.45806

Key Eligibility Criteria

  • Voluntarily agrees to participate in the clinical trial; is fully informed about the study and has signed the informed consent form (ICF); is willi…
  • Male or female patients aged ≥8 weeks.
  • Histologically confirmed diagnosis of advanced bone and soft tissue sarcoma, who have failed or are intolerant to prior standard therapies.
  • At least one measurable lesion as defined by RECIST version 1.1.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Osteosarcoma Sarcoma Trials on Trialify →